<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10555755</article-id><article-id pub-id-type="pmc">2374302</article-id><article-id pub-id-type="pii">6690773</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berruti</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Borasio</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gerbino</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gorzegno</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moschini</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">3</xref></contrib><contrib contrib-type="author"><name><surname>Tampellini</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ardissone</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brizzi</surname><given-names>M P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dolcetti</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">3</xref></contrib><contrib contrib-type="author"><name><surname>Dogliotti</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dipartimento di Scienze Cliniche e Biologiche, Oncologia Medica, Universit&#x000e0; di Torino, Torino Italy</aff><aff id="aff2"><label>2</label>Unit&#x000e0; Operativa Autonoma di Chirurgia Toracica <label>3</label>Unit&#x000e0; Operativa Autonoma di Pneumologia, <label>4</label>1&#x02013;3 Azienda Ospedaliera San Luigi, Regione Gonzole 10, 10043 Orbassano, Italy</aff><pub-date pub-type="ppub"><month>11</month><year>1999</year></pub-date><volume>81</volume><issue>5</issue><fpage>841</fpage><lpage>845</lpage><history><date date-type="received"><day>23</day><month>10</month><year>1998</year></date><date date-type="rev-recd"><day>21</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>30</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>From 1990 to 1997, 16 consecutive patients with stage III and IVa invasive thymoma were treated in a single institution with primary chemotherapy consisting in adriamycin (40 mg m<sup>&#x02013;2</sup>), cisplatin (50 mg m<sup>&#x02013;2</sup>) administered intravenously on day 1, vincristine (0.6 mg m<sup>&#x02013;2</sup>) on day 2 and cyclophosphamide (700 mg m<sup>&#x02013;2</sup>) on day 4 (ADOC). The courses were repeated every 3 weeks. The aim was to evaluate the impact of this cytotoxic regimen with respect to response rate, per cent of patients radically resected, time to progression and overall survival. Two complete responses (one clinical and one pathological) and 11 partial responses were observed (overall response rate 81.2&#x00025;); two patients had stable disease and one progressed. Toxicity was mild as only two patients developed grade III/IV neutropenia and one patient grade III nausea/vomiting. Nine patients were radically resected (five out of ten with stage III, and four out of six with stage IVa). Median time to progression and overall survival was 33.2 and 47.5 months respectively. Three patients were alive and disease free after more than 5 years. The ADOC scheme is highly active and manageable in the treatment of locally advanced thymoma. As a preoperative approach it should be offered to patients not amenable to surgery or to those surgically resectable but with a great deal of morbidity. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>primary chemotherapy</kwd><kwd>thymome</kwd><kwd>radiotherapy</kwd></kwd-group></article-meta></front></article>


